User:Mr. Ibrahem/Neratinib

From Wikipedia, the free encyclopedia
< User:Mr. Ibrahem

This is the current revision of this page, as edited by Mr. Ibrahem (talk | contribs) at 21:26, 3 February 2024 (from https://mdwiki.org/wiki/Neratinib). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Mr. Ibrahem/Neratinib
Clinical data
Trade namesNerlynx, Hernix
Other namesHKI-272
AHFS/Drugs.comMonograph
MedlinePlusa617034
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor[1]
Legal status
Legal status
Identifiers
  • (2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
Chemical and physical data
FormulaC30H29ClN6O3
Molar mass557.05 g·mol−1
3D model (JSmol)
  • CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C
  • InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+ checkY
  • Key:JWNPDZNEKVCWMY-VQHVLOKHSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Neratinib, sold under the brand name Nerlynx, is a medication used to treat breast cancer.[3][4] Specifically it is used for HER2 positive and hormone-receptor positive cases following surgery and trastuzumab.[4] It is taken by mouth.[1]

Diarrhea affects nearly all people.[4] Other common side effects include nausea, tiredness, belly pain, rash, inflamed mouth, and muscle spasms.[4] Other side effects may include liver problems.[1] Use in pregnancy may harm the baby.[1] It is a tyrosine kinase inhibitor which blocks HER2, HER4, and EGFR.[1]

Neratinib was approved for medical use in the United States in 2017 and Europe in 2018.[1][4] In the United States it costs 19,200 USD per month as of 2021.[5] In the United Kingdom this amount costs about £4,500.[6]

References[edit]

  1. ^ a b c d e f "Neratinib Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 12 November 2021.
  2. ^ "Nerlynx 40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 28 October 2021. Retrieved 13 November 2020.
  3. ^ a b c "Nerlynx- neratinib tablet". DailyMed. 6 August 2020. Archived from the original on 18 November 2020. Retrieved 13 November 2020.
  4. ^ a b c d e f g "Nerlynx EPAR". European Medicines Agency (EMA). Archived from the original on 20 November 2020. Retrieved 13 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ "Nerlynx Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 April 2021. Retrieved 12 November 2021.
  6. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1035. ISBN 978-0857114105.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Neratinib&oldid=1202935637"